Novartis CEO interview puts Reuters ahead of pack

Reuters subscribers got a jump start on Novartiss strategic thinking on Nov 17 when the Swiss drugmakers CEO Joe Jimenez spelled out his ideas on margins, acquisitions and Alcon in an interview. Reuters was the only news agency to talk to Jimenez ahead of a keenly awaited investor briefing in London. His comments on expecting improved operating income margins despite patent losses, seeking $1-2 billion bolt-on acquisitions and maintaining an equity-based offer for Alcon minorities were reiterated several hours later during the briefing and cited in notes from brokers, including Morgan Stanley and Credit Agricole Cheuvreux. The initial Reuters headlines on the Alcon offer also prompted a series of calls from Alcon shareholders seeking further details. Novartis shares rose 2 percent the following day as investors warmed to its message that long-term profitability would improve, despite tough market conditions.